Annals of Hematology

, Volume 85, Issue 6, pp 394–399

Vinorelbine plus intermediate dose cyclophosphamide is an effective and safe regimen for the mobilization of peripheral blood stem cells in patients with multiple myeloma

Authors

  • Mario Annunziata
    • Division of Hematology and Stem Cell Transplantation UnitCardarelli Hospital
  • Maria Celentano
    • Division of Hematology and Stem Cell Transplantation UnitCardarelli Hospital
  • Barbara Pocali
    • Division of Hematology and Stem Cell Transplantation UnitCardarelli Hospital
  • Maria Rosaria D’Amico
    • Division of Hematology and Stem Cell Transplantation UnitCardarelli Hospital
  • Salvatore Palmieri
    • Division of Hematology and Stem Cell Transplantation UnitCardarelli Hospital
  • Assunta Viola
    • Division of Hematology and Stem Cell Transplantation UnitCardarelli Hospital
  • Carolina Copia
    • Division of Hematology and Stem Cell Transplantation UnitCardarelli Hospital
  • Claudio Falco
    • Division of Hematology and Stem Cell Transplantation UnitCardarelli Hospital
    • Service of Transfusion MedicineCardarelli Hospital
  • Luigi Del Vecchio
    • Division of Hematology and Stem Cell Transplantation UnitCardarelli Hospital
    • Service of Transfusion MedicineCardarelli Hospital
    • Division of Hematology and Stem Cell Transplantation UnitCardarelli Hospital
    • Via Nicolò Piccinni 6
Original Article

DOI: 10.1007/s00277-005-0058-0

Cite this article as:
Annunziata, M., Celentano, M., Pocali, B. et al. Ann Hematol (2006) 85: 394. doi:10.1007/s00277-005-0058-0

Abstract

High dose cyclophosphamide (HD-Cy) is commonly used to mobilize stem cells in multiple myeloma (MM). However, timing of collection is variable and incidence of side effects is substantial. We evaluated a combination of vinorelbine (VNB) (25 mg/m2 day 1) plus Cy (1.5 g/m2 day 2) and G-CSF as mobilizing regimen in 37 patients with MM. Results were compared to those achieved in 41 previously diagnosed patients mobilized with Cy at 4 g/m2. Overall, 36/37 patients receiving VNB–Cy (97%) mobilized, as opposed to 40/41 (97%) in the controls (p:0.51). Median CD34+ cells peak was 94/μl for VNB–Cy patients and 96 for controls, p=0.36; median number of CD34+ cells collected was 9.2×106/kg and 8.7×106/kg, respectively (p=0.85). Median number of days to the highest CD34 count was shorter for VNB–Cy patients (nine vs 11, p=0.001). No VNB–Cy patient experienced grade 3–4 neutropenia and thrombocytopenia, as opposed to 63 and 19% in the controls (p=0.001 and 0.01, respectively). Hospitalization from toxicity was never required in VNB–Cy patients as compared to 19% in control group (p=0.01). We conclude that an outpatient combination of VNB plus intermediate dose Cy plus G-CSF is a safe, predictable, and highly effective mobilization regimen for patients with newly-diagnosed MM.

Keywords

Stem cell Mobilization Multiple myeloma Vinorelbine Cyclophosphamide

Copyright information

© Springer-Verlag 2006